Back to search



Awarded: NOK 74,999

Project Manager:

Project Number:


Project Period:

2023 - 2023



Subject Fields:

Cancer-related cachexia is connected with significant weight and muscle loss is observed in 50% of the cases and is a deadly condition associated with chemotherapy. No standard treatment for this condition is presently available. In these patients, a high level of proinflammatory cytokines is observed. The yearly number of cancer deaths worldwide is around 10 million, of which about 30% can be related to cachexia. In 2020, EU27 had an incidence of new cancer cases of 2,7 million with approximately 1,3 million cancer-related deaths, of which as many as 400 thousand – about 30 % – may potentially be linked to cachexia. There are currently no effective remedies for cancer-induced cachexia on the market. Our innovation, AndoSan, is an extract based on 3 mushrooms. AndoSan is produced through a unique proprietary process leading to unique chemical composition. Even though the immunomodulating effects of AndoSan have been studied extensively, its potential for cancer cachexia has just recently become evident. A surprising 50 % to 90 % reduction in levels of proinflammatory cytokines such as TNF-a and IL-6 observed in recently conducted cell assay combined with post-analysis of clinical pilot trials in humans focused on other indications strongly suggests a potentially game-changing role for AndoSan as a novel treatment of cancer cachexia.

Funding scheme: